Netherlands· NL-4de92f32d996
GONAL-f 300 I.E./0,5 ml oplossing voor injectie in een voorgevulde pen
A follitropin alfa product containing follitropine alfa, registered in Netherlands by Merck Europe B.V.. The same ATC class is registered in 12 of our 19 countries.
Checked against CBG-MEB (Netherlands) on
Informational only — not a medical device.
Where it is registered
Follitropin alfa is registered in 12 of 19 countries.
Countries holding a registration under ATC G03GA05 (follitropin alfa), each read from that country’s own register.
- This record: Netherlands, from CBG-MEB (Netherlands)
- 7 of them publish a price we can compare per daily dose
Follitropin alfa · ATC G03GA05
12 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Ireland
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
The record
At a glance
CBG-MEB (Netherlands)- Active substance
- FOLLITROPINE ALFA
- Manufacturer
- Merck Europe B.V.
- Country
- Netherlands (NL)
- ATC code
- G03GA05
- ATC class
- Follitropin alfa
- Defined daily dose
- 75 E, P
- Reimbursed
- Not published by this register
- Source register
- CBG-MEB (Netherlands)
- Last checked
- September 29, 2026
Packs & prices · 1
- cbg_meb_idEU/1/95/001
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Follitropin alfa in 15 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- United KingdomBemfola 150units/0.25ml solution for injection pre-filled pensGedeon Richter (UK) Ltd
- CzechiaBEMFOLAGedeon Richter Plc., Budapešť
- SpainBEMFOLA 150 UI/0,25 ml solucion inyectable en pluma precargadaGedeon Richter Plc.
- FinlandBemfolaGedeon Richter Plc
- BelgiumBemfola 150 IU/0.25 mlGedeon Richter
- ItalyBEMFOLA*1 cartuccia in penna preriempita SC 150 UI/0,25 ml + agoGEDEON RICHTER PLC
- SwedenBemfola 150 IE/0,25 ml Injektionsvätska, lösning i förfylld injektionspennaGedeon Richter Plc
- PolandBemfolaGedeon Richter Plc.
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Bemfola, Gonal-F
- Liechtenstein · Bemfola, Gonal-F
- Norway · Bemfola, Gonal-F
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of CBG-MEB (Netherlands). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/cd361e72-afb8-4eb7-ab6d-b9fc8c856b3c GET /v1/drugs/cd361e72-afb8-4eb7-ab6d-b9fc8c856b3c?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Oplossing voor injectie",
"route": "Subcutaan gebruik",
"soort": null,
"source": "cbg_meb",
"smpc_url": "https://www.ema.europa.eu/en/documents/product-information/gonal-f-epar-product-information_nl.pdf",
"strength": null,
"atc_label": "Follitropin Alfa",
"detail_url": "https://www.geneesmiddeleninformatiebank.nl/nl/cp71825",
"excipients": [
"DINATRIUMWATERSTOFFOSFAAT 2-WATER (E 339)",
"FOSFORZUUR (E 338)",
"METACRESOL",
"METHIONINE, (L-)",
"NATRIUMDIWATERSTOFFOSFAAT 1-WATER (E 339)",
"NATRIUMHYDROXIDE (E 524)",
"POLOXAMEER 188",
"SACCHAROSE",
"WATER VOOR INJECTIE"
],
"substances": [
"FOLLITROPINE ALFA"
],
"leaflet_url": null,
"authorised_at": "2004/02/23",
"procedure_number": "EMEA/H/C/000071",
"dispensing_status": "Uitsluitend recept",
"registration_number": "EU/1/95/001",
"additional_monitoring": "N"
}See everything about follitropin alfa.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.